Industry Briefs: December 10, 2012 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Industry Briefs: December 10, 2012
A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers.


Company News

Amorfix Life Sciences has established a collaboration with CNJ Holdings, a wholly owned subsidiary of Cangene, for the identification and development of therapeutic antibodies against proprietary disease specific epitopes identified using Amorfix’s ProMIS discovery technology for treating various oncology indications. Read More

AMRI has extended its commercial supply relationship with GE Healthcare for aminobisamide hydrochloride. Read More

Impact Analytical announced an expansion that includes new testing and analysis laboratories. The project is scheduled to be completed by March 2013. Read More

Kemwell has signed an agreement with Mercury Pharma for the manufacturing of pharmaceuticals at its new production facility in Uppsala, Sweden. Read More

Sartorius Stedim Biotech has launched its Sartoguard NF prefilter series, featuring a combination of high-performance polyethersulfone membranes and nanofleece technology. Read More

People News

AAIPharma has appointed Timothy Rhines as senior director of biopharmaceutical Development. Read More

In addition, AAIPharma has also appointed David Browne director of analytical chemistry. Read More

AmerisourceBergen has named Peyton R. Howell senior vice-president of AmerisourceBergen Corporation, and president of global sourcing and manufacturer relationships. Read More

Pfizer has elected CEO Ian Read as chairman of the board. Read More

Roche has announced several changes to its board of directors, and has proposed CEO Severin Schwan as a new member of the board. Read More

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality

Click here